Losartan alone vs. with hydrochlorothiazide for kidney protection
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial compares two blood pressure treatments—losartan by itself versus losartan combined with hydrochlorothiazide—to see which better protects the kidneys in people with diabetic kidney disease. You may join if you have protein in your urine and your kidney function is still relatively good.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have protein or albumin in your urine at the time of screening.
- Your kidney function (creatinine clearance) is 30 mL/min or higher.
- You have diabetic kidney disease (not another type of kidney disease).
- You do not have type 1 diabetes.
- You have not had a heart attack or stroke in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if a combination drug (sacubitril/valsartan) can help control blood pressure and protect the kidneys in people with both high blood pressure and type 2 diabetes who have early signs of kidney damage.
This trial tests if a new treatment combination (finerenone plus a water pill) works better than a standard fixed-dose combination for people with both high blood pressure and chronic kidney disease. It aims to find which option provides more clinical benefit.
This trial tests whether combining dapagliflozin (a water-pill-like diabetes drug) with finerenone (a kidney-protective medication) works better than dapagliflozin alone for people with type 2 diabetes and kidney damage. Both drugs help reduce protein in urine and may slow kidney disease progression.
This trial is for people with high blood pressure and high cholesterol. It checks whether taking a combination of blood pressure medicine (fimasartan) with cholesterol medicines (atorvastatin and ezetimibe) can protect the kidneys better than just the first two drugs alone.
This trial tests whether a new drug, HTD1801, can protect or improve kidney function in people with type 2 diabetes and chronic kidney disease. It may help slow kidney damage and reduce protein in urine.
This trial tests an intervention to help adults with type 2 diabetes who have “high-normal” blood pressure (not severely high). If you qualify, you may learn whether this approach improves blood pressure and related health outcomes over time.
Hear when a new Proteinuria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.